A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis

Silva, Carolina Nunes da; Silva, Flávia Rodrigues da; Dourado, Lays Fernanda Nunes; Reis, Pablo Victor Mendes Dos; Silva, Rummenigge Oliveira; Costa, Bruna Lopes da; Nunes, Paula Santos; Amaral, Flávio Almeida; Santos, Vera Lúcia dos; Lima, Maria Elena de; Silva-Cunha, Armando

doi:10.3390/toxins11040203

Cited by 24 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For examples, a topical eye drops formulation containing LyeTxI-b recently has showed effective in the treatment of keratitis with resistant bacterial while no signs of ocular toxicity found. In more details, LyeTxI-b could eliminate bacteria and reduce both inflammatory cellular activity and biofilm viability in the eyes [ 80 ]. In development of artificial corneal skirt, the corneas with AMP-immobilized Titan ( via a cross-linker – polydopamine) compared to those with unprotected Titan implants, showed lower incidence and lesser extent of bacterial infection [ 81 ].…”

Section: Applications Of Amps In Some Infectious Diseasesmentioning

confidence: 99%

Antimicrobial peptides – Advances in development of therapeutic applications

2020

View full text Add to dashboard Cite

The severe infection is becoming a significant health problem which threaten the lives of patients and the safety and economy of society. In the way of finding new strategy, antimicrobial peptides (AMPs) - an important part of host defense family, emerged with tremendous potential. Up to date, huge numbers of AMPs has been investigated from both natural and synthetic sources showing not only the ability to kill microbial pathogens but also propose other benefits such as wound healing, anti-tumor, immune modulation. In this review, we describe the involvements of AMPs in biological systems and discuss the opportunity in developing AMPs for clinical applications. In the detail, their properties in antibacterial activity is followed by their application in some infection diseases and cancer. The key discussions are the approaches to improve biological activities of AMPs either by modifying chemical structure or incorporating into delivery systems. The new applications and perspectives for the future of AMPs would open the new era of their development.

show abstract

Section: Applications Of Amps In Some Infectious Diseasesmentioning

confidence: 99%

Antimicrobial peptides – Advances in development of therapeutic applications

2020

View full text Add to dashboard Cite

show abstract

“…21 and adapted by Ref. 22. The fertilized eggs were incubated at 37 ± 1°C and 60 ± 1% relative humidity, for 10 days.…”

Section: Evaluation Of Pnpp-19 Toxicity Through Hen's Egg Test In Chomentioning

confidence: 99%

PnPP-19 Peptide as a Novel Drug Candidate for Topical Glaucoma Therapy Through Nitric Oxide Release

Silva

Dourado

Lima

et al. 2020

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is very effective in the treatment of keratitis, with no signs of ocular toxicity in an in vivo eye infection model induced by the same bacterium. 13…”

Section: Introductionmentioning

confidence: 99%

Shortened derivatives from native antimicrobial peptide LyeTx I: In vitro and in vivo biological activity assessment

Fuscaldi

Júnior

Santos

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

In the continuing search for novel antibiotics, antimicrobial peptides are promising molecules, due to different mechanisms of action compared to classic antibiotics and to their selectivity for interaction with microorganism cells rather than with mammalian cells. Previously, our research group has isolated the antimicrobial peptide LyeTx I from the venom of the spider Lycosa erythrognatha. Here, we proposed to synthesize three novel shortened derivatives from LyeTx I (LyeTx I mn; LyeTx I mnΔK; LyeTx I mnΔKAc) and to evaluate their toxicity and biological activity as potential antimicrobial agents. Peptides were synthetized by Fmoc strategy and circular dichroism analysis was performed, showing that the three novel shortened derivatives may present membranolytic activity, like the original LyeTx I, once they folded as an alpha helix in 2.2.2-trifluorethanol and sodium dodecyl sulfate. In vitro assays revealed that the shortened derivative LyeTx I mnΔK presents the best score between antimicrobial (↓ MIC) and hemolytic (↑ EC50) activities among the synthetized shortened derivatives, and LUHMES cell-based NeuriTox test showed that it is less neurotoxic than the original LyeTx I (EC50 [LyeTx I mnΔK] ⋙ EC50 [LyeTx I]). In vivo data, obtained in a mouse model of septic arthritis induced by Staphylococcus aureus, showed that LyeTx I mnΔK is able to reduce infection, as demonstrated by bacterial recovery assay (∼10-fold reduction) and scintigraphic imaging (less technetium-99m labeled-Ceftizoxime uptake by infectious site). Infection reduction led to inflammatory process and pain decreases, as shown by immune cells recruitment reduction and threshold nociception increment, when compared to positive control group. Therefore, among the three shortened peptide derivatives, LyeTx I mnΔK is the best candidate as antimicrobial agent, due to its smaller amino acid sequence and toxicity, and its greater biological activity.

show abstract

A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis

Cited by 24 publications

References 34 publications

Antimicrobial peptides – Advances in development of therapeutic applications

Antimicrobial peptides – Advances in development of therapeutic applications

PnPP-19 Peptide as a Novel Drug Candidate for Topical Glaucoma Therapy Through Nitric Oxide Release

Shortened derivatives from native antimicrobial peptide LyeTx I: In vitro and in vivo biological activity assessment

Contact Info

Product

Resources

About